TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$50 Million

Genocea Biosciences

Follow-on Offering

Bookrunner, July 2015

Genocea Biosciences
Confidentially Marketed Public Offering

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.